Skip to main content

Advertisement

Table 1 Associations of PGK1 S203 and PDHK1 T338 phosphorylation levels with clinicopathologic characteristics in patients with BRCA, LIHC, LUAD, STAD and ESCA

From: Associations of PGK1 promoter hypomethylation and PGK1-mediated PDHK1 phosphorylation with cancer stage and prognosis: a TCGA pan-cancer analysis

Cancer type Characteristic Total (cases) PGK1 pS203 (IHC staining score) PDHK1 pT338 (IHC staining score)
Mean 95% CI P value Mean 95% CI P value
BRCA Age (years)     0.478    0.975
 ≤ 60 96 4.70 4.34–5.06   4.99 4.60–5.38  
 > 60 49 4.92 4.41–5.42   5.00 4.47–5.53  
TNM stagea     0.027    0.018
 I/II 95 4.54 4.18–4.90   4.73 4.34–5.11  
 III/IV 48 5.23 4.73–5.73   5.52 4.99–6.06  
LIHC Age (years)        
 ≤ 60 75 4.28 3.91–4.65 0.615 4.31 3.96–4.66 0.406
 > 60 110 4.42 4.06–4.78   4.52 4.19–4.85  
Gender     0.138    0.365
 Male 159 4.44 4.17–4.71   4.47 4.22–4.72  
 Female 26 3.88 3.10–4.67   4.15 3.39–4.92  
TNM stageb     0.643    0.226
 I/II 73 4.18 3.81–4.55   4.16 3.83–4.50  
 III/IV 104 4.30 3.95–4.64   4.46 4.13–4.79  
LUAD Age (years)     0.763    0.385
 ≤ 60 84 4.71 4.44–4.99   4.85 4.54–5.15  
 > 60 95 4.78 4.46–5.10   4.65 4.34–4.97  
Gender     0.722    0.700
 Male 104 4.72 4.45–4.99   4.71 4.42–5.00  
 Female 75 4.79 4.45–5.14   4.79 4.45–5.14  
TNM stage     0.339    0.236
 I/II 105 4.65 4.36–4.94   4.62 4.33–4.91  
 III/IV 74 4.86 4.54–5.18   4.89 4.56–5.22  
STAD Age (years)     0.665    0.638
 ≤ 60 56 4.55 4.18–4.93   4.61 4.21–5.01  
 > 60 39 4.69 4.14–5.24   4.44 3.82–5.05  
Gender     0.149    0.593
 Male 60 4.78 4.39–5.18   4.47 4.01–4.92  
 Female 35 4.31 3.81–4.82   4.66 4.14–5.18  
TNM stagec     0.356    0.195
 I/II 24 4.88 4.19–5.56   4.96 4.26–5.66  
 III/IV 69 4.54 4.17–4.90   4.45 4.06–4.84  
ESCA Age (years)     0.781    0.089
 ≤ 60 112 4.58 4.23–4.93   4.63 4.30–4.96  
 > 60 102 4.65 4.33–4.97   5.03 4.71–5.34  
Gender     0.559    0.216
 Male 176 4.58 4.31–4.84   4.76 4.50–5.01  
 Female 38 4.76 4.23–5.29   5.13 4.56–5.70  
TNM stage     0.006    0.008
 I/II 98 4.26 3.89–4.62   4.49 4.14–4.84  
 III/IV 116 4.91 4.61–5.22   5.1 4.81–5.40  
  1. BRCA breast carcinoma, LIHC liver hepatocellular carcinoma, LUAD lung adenocarcinoma, STAD stomach adenocarcinoma, ESCA esophageal carcinoma, 95% CI 95% confidence interval, PGK1 pS203 PGK1 S203 phosphorylation level, PDHK1 pT338 PDHK1 T338 phosphorylation level
  2. aThe data of TNM stage in BRCA were available in 143 patients
  3. bThe data of TNM stage in LIHC were available in 177 patients
  4. cThe data of TNM stage in STAD were available in 93 patients